PACIFIC
- 2022年
- mPFS 16.9月 vs 5.6月
- mOS 47.5月 vs 29.1月
GEMSTONE-301
PACIFIC-5
参考文献
[1]Antonia SJ, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2021;39(15):1647-1657.
[2]Wu YL, Wu L, Bi N, et al. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. Journal of Hematology & Oncology. 2025;18(1):111.
[3]Zhang Z, Bi N, Wang Y, et al. The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist). J Clin Oncol. 2025;43(16_suppl):8012.
[4]Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024;391(7):585-597.
[5]Meng X, et al. Aumolertinib as consolidation therapy for unresectable stage III EGFR-mutated NSCLC: The phase III POLESTAR trial. Presented at 2024 WCLC, Abstract PL04.13. J Thorac Oncol. 2024.
[6]Bi N, Wang JY, Jiang W, et al. Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data. J Clin Oncol. 2025;43(16_suppl):8048.
[7]Tan F, Jiang Y, Duan J, et al. Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients. J Natl Cancer Cent. 2026;6(2):159-165.
|